QCM
PTCT icon

QRG Capital Management’s PTC Therapeutics PTCT Stock Holding History

QRG Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.04M Sell
24,989
-1,034
-4% -$74.7K 0.02% 464
2026
Q1 		$1.77M Buy
26,023
+4,312
+20% +$305K 0.02% 446
2025
Q4 		$1.65M Sell
21,711
-12,348
-36% -$897K 0.02% 447
2025
Q3 		$2.09M Buy
+34,059
New +$1.77M 0.03% 381

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

QRG Capital Management's PTCT Position: Q2 2026 in Review

QRG Capital Management reduced its PTC Therapeutics (PTCT) stake by 4% in Q2 2026, selling an estimated $74.7K and leaving 24,989 shares worth $2.04M. The position accounts for 0.02% of the portfolio, ranked #464.

QRG Capital Management first reported a position in PTCT in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.09M in Q3 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • QRG Capital Management held 24,989 shares of PTC Therapeutics worth $2.04M as of Q2 2026.
  • QRG Capital Management sold 1,034 PTC Therapeutics shares in Q2 2026, an estimated $74.7K.
  • PTC Therapeutics made up 0.02% of QRG Capital Management's portfolio in Q2 2026, its #464 holding.
  • QRG Capital Management first reported a position in PTC Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • QRG Capital Management's PTC Therapeutics position peaked at $2.09M in Q3 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on QRG Capital Management's 13F filing for Q2 2026, filed 14 Jul 2026.